Praful Ravi

Dr. Praful Ravi


Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 April 2021 in BJU International
Verified
Journal Article
Closed access
PDF file
PRPraful Ravi
Praful Ravi
GPGregory R. Pond
Gregory R. Pond
LDLeonidas N. Diamantopoulos
Leonidas N. Diamantopoulos
CSChristopher Su
Christopher Su
AAAjjai Alva
Ajjai Alva
GSGuru P. Sonpavde
Guru P. Sonpavde

28 September 2020 in The Prostate
Verified
Journal Article
Closed access
PDF file
CVCecile Vicier
Cecile Vicier
PRPraful Ravi
Praful Ravi
LKLucia Kwak
Lucia Kwak
LWLillian Werner
Lillian Werner
YHYing Huang
Ying Huang
CSChristopher J. Sweeney
Christopher J. Sweeney

1 January 2014 in Urologic Oncology: Seminars and Original Investigations
Verified
Journal Article
Closed access
MSMaxine Sun
Maxine Sun
PRPraful Ravi
Praful Ravi
PKPierre I. Karakiewicz
Pierre I. Karakiewicz
SSShyam Sukumar
Shyam Sukumar
JSJesse Sammon
Jesse Sammon
MLMuhieddine Labban
Muhieddine Labban

20 June 2024 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
LKLucia Kwak
Lucia Kwak
PRPraful Ravi
Praful Ravi
JAJohn G. Armstrong
John G. Armstrong
VBVeronique Beckendorf
Veronique Beckendorf
JCJoseph L. Chin
Joseph L. Chin
CSChristopher J. Sweeney
Christopher J. Sweeney
PURPOSE: We sought to evaluate the prognostic impact of prostate-specific antigen (PSA) at 6 months after completion of radiotherapy (RT) in patients treated with RT alone, RT plus short-term (st; 3-6 months), and RT plus long-term (lt; 24-36 months) androgen-deprivation therapy (ADT). PATIENTS AND METHODS: Individual patient data were obtained from 16 randomized trials evaluating RT ± ADT for localized prostate cancer (PCa) between 1987 and 2011. The lowest PSA recorded within 6 months after RT completion was identified and categorized as < or ≥0.1 ng/mL. The primary outcomes were metastasis-free survival (MFS), PCa-specific mortality (PCSM), and overall survival (OS), from 12 months after random assignment. RESULTS: Ninety-eight percent (n = 2,339/2,376) of patients allocated to RT alone, 84% (n = 4,756/5,658) allocated to RT + stADT, and 77% (n = 1,258/1,626) allocated to RT + ltADT had PSA ≥0.1 ng/mL within 6 months after completing RT. PSA ≥0.1 ng/mL was associated with lower MFS and OS and higher PCSM among patients allocated to RT ± ADT (RT – MFS: hazard ratio [HR], 2.24 [95% CI, 1.21 to 4.16]; PCSM: subdistribution hazard ratio [sHR], 1.82 [0.51 to 6.49]; OS: HR, 1.72 [0.97 to 3.05]; RT + stADT – MFS: HR, 1.27 [1.12 to 1.44]; PCSM: sHR, 2.10 [1.52 to 2.92]; OS: HR, 1.26 [1.11 to 1.44]; RT + ltADT – MFS: HR, 1.58 [1.27 to 1.96]; PCSM: sHR, 1.97 [1.11 to 3.49]; OS: HR, 1.59 [1.27 to 1.99]). Five-year MFS rates among patients allocated to RT, RT + stADT, and RT + ltADT were 91% versus 79%, 83% versus 76%, and 87% versus 74%, respectively, based on PSA < or ≥0.1 ng/mL. CONCLUSION: PSA ≥0.1 ng/mL within 6 months after RT completion was prognostic for lt outcomes in patients treated with RT ± ADT for localized PCa. This can be used to counsel patients treated with RT ± ADT and in guiding clinical trial design evaluating novel systemic therapies with RT + ADT as well as (de)intensification strategies.

26 January 2023 in Journal of Nuclear Medicine
Verified
Journal Article
Open access
PDF file
PRPraful Ravi
Praful Ravi
BWBridget Whelpley
Bridget Whelpley
EKEmma Kelly
Emma Kelly
AWAndrew Wolanski
Andrew Wolanski
JRJolivette Ritzer
Jolivette Ritzer
HJHeather Jacene
Heather Jacene
In March 2022, 177 Lu-PSMA-617 (177 Lu-vipivotide tetraxetan) received Food and Drug Administration approval for treatment of metastatic castration-resistant prostate cancer (mCRPC) in men with prostate-specific membrane antigen (PSMA)-avid disease who have received prior chemotherapy and a novel androgen receptordirected therapy (1). Approval followed the VISION trial, which demonstrated a median 4-mo overall survival benefit for 177 Lu-PSMA-617 plus best supportive care versus best supportive care alone (2). 177 Lu-PSMA-617 is the first theranostic agent for prostate cancer and a clinically meaningful addition to the therapeutic armamentarium. Here, we describe the process of clinical implementation of 177 Lu-PSMA-617 at a major academic center, highlighting successes and challenges. Between May and October 2022, 146 patients with a median age of 73 y were referred for 177 Lu-PSMA-617 therapy at Dana-Farber Cancer Institute. Cognizant of potential access issues, once 177

5 December 2023 in Annals of Oncology
Verified
Journal Article
Closed access
WXW. Xie
W. Xie
PRPraful Ravi
Praful Ravi
MBM. Buyse
M. Buyse
SHS. Halabi
S. Halabi
PKP. Kantoff
P. Kantoff
CSC.J. Sweeney
C.J. Sweeney